Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Change in Acquisitions & Divestments (2016 - 2025)

Vanda Pharmaceuticals' Change in Acquisitions & Divestments history spans 16 years, with the latest figure at $47.0 million for Q4 2025.

  • For Q4 2025, Change in Acquisitions & Divestments fell 51.35% year-over-year to $47.0 million; the TTM value through Dec 2025 reached $208.2 million, down 40.85%, while the annual FY2025 figure was $208.2 million, 40.85% down from the prior year.
  • Change in Acquisitions & Divestments for Q4 2025 was $47.0 million at Vanda Pharmaceuticals, up from $35.6 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $350.4 million in Q1 2023 and bottomed at $35.6 million in Q3 2025.
  • The 5-year median for Change in Acquisitions & Divestments is $85.1 million (2022), against an average of $95.3 million.
  • The largest annual shift saw Change in Acquisitions & Divestments skyrocketed 289.0% in 2023 before it crashed 82.73% in 2024.
  • A 5-year view of Change in Acquisitions & Divestments shows it stood at $79.4 million in 2021, then rose by 0.74% to $80.0 million in 2022, then surged by 40.14% to $112.1 million in 2023, then decreased by 13.83% to $96.6 million in 2024, then tumbled by 51.35% to $47.0 million in 2025.
  • Per Business Quant, the three most recent readings for VNDA's Change in Acquisitions & Divestments are $47.0 million (Q4 2025), $35.6 million (Q3 2025), and $38.0 million (Q2 2025).